Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. (Q38168893)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

2 March 2020

main subject

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Praveen Vikas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Mohamad Mohty

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Bipin N Savani

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

6 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

301-315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Signal transduction of oncogenic Flt3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Antitumor activity of sorafenib in FLT3-driven leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.857596

10.1586/17474086.2014.857596

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308526%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference